Showing results (161-170 of 212) with videos related to

Sort By:
Pageof 22
Molecular Cancer Therapeutics|January 24, 2012
CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapyAdam Siddiqui-Jain, Joshua Bliesath, Diwata Macalino, et al.
Investigational New Drugs|September 28, 2014
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumorsRobert M Jotte, Daniel D Von Hoff, Fadi Braiteh, et al.
Cancer Discovery|March 24, 2017
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid TumorsDejan Juric, Ian Krop, Ramesh K Ramanathan, et al.
Urologic Oncology|December 5, 2009
Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancerGuru Sonpavde, Ana M Aparicio, Feng Zhan, et al.
The Oncologist|January 23, 2025
Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreductionVincent Chung, Angela Alistar, Carlos Becerra, et al.
Journal of the National Cancer Institute|February 2, 2015
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trialDavid Goldstein, Robert Hassan El-Maraghi, Pascal Hammel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2011
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumorsPatricia M LoRusso, Charles M Rudin, Josina C Reddy, et al.
BMC Medical Genomics|June 20, 2014
Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancerVijayalakshmi Shanmugam, Ramesh K Ramanathan, Nicole A Lavender, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignanciesLillian L Siu, Eric K Rowinsky, Lisa A Hammond, et al.
Journal of Gastrointestinal Oncology|January 5, 2018
A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patientsRamesh K Ramanathan, Glen J Weiss, Richard G Posner, et al.
Pageof 22